Development asset linked to Turn Therapeutics in public FDA and regional records.
pharma · Advanced solid tumors · Advanced Solid Tumors · TTRX
Turn Therapeutics
Turn Therapeutics drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Westlake Village, USA HQ
2015 Founded
11 Employees
Public company Type
TTRX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Westlake Village, USA
- Founded
- 2015
- Employees
- 11
- Programs
- 6
- Drugs
- 3
- Patents
- 40
Turn Therapeutics pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Turn Therapeutics drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Turn Therapeutics in public FDA and regional records.
-
repotrectinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: CD74-ROS1.
- Target
- CD74-ROS1
- Mechanism
- CD74-ROS1 inhibitor